Fibrodysplasia ossificans progressiva (FOP) clinical study program

Please refer to the approved USPI for full prescribing information

Fibrodysplasia ossificans progressiva (FOP) clinical study program

Please refer to the approved USPI for full prescribing information

Click on the buttons below to find out about Ipsen-sponsored studies in FOP:

Natural History Study
NCT02322255

A global non-interventional natural history study (NHS) which followed the progression of FOP over 36 months in a cohort of patients¹

Burden of Illness Survey
NCT04665323

An international cross-sectional survey which assessed physical, quality of life, and economic impacts of FOP on patients and their families²

MOVE Trial
NCT03312634

A Phase III, 48-month study to evaluate the efficacy and safety of palovarotene in patients with FOP, compared with untreated participants from the FOP NHS^3,4

PIVOINE Trial
NCT05027802

A Phase III, open-label roll-over study to further evaluate the safety and efficacy of palovarotene in patients with FOP who have previously received palovarotene in an eligible parent study⁶

FALKON Trial
NCT05039515

A Phase II, 63-month study to evaluate the efficacy of two dosing regimens of oral fidrisertib* in inhibiting new heterotopic ossification volume compared with placebo in patients with FOP⁵

*Fidrisertib has not been FDA-approved for any indication and efficacy and safety have not been established.